Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 89


Aspirin for Primary Prevention of Cardiovascular Diseases: Current Concepts, Unanswered Questions and Future Directions.

Castro-Torres Y, Katholi RE, Yar Khan N.

Hellenic J Cardiol. 2015 Nov-Dec;56(6):461-74. No abstract available.


Ventricular repolarization markers for predicting malignant arrhythmias in clinical practice.

Castro-Torres Y, Carmona-Puerta R, Katholi RE.

World J Clin Cases. 2015 Aug 16;3(8):705-20. doi: 10.12998/wjcc.v3.i8.705. Review.


Natriuretic peptides, obesity and cardiovascular diseases.

Castro-Torres Y, Katholi RE.

Rev Assoc Med Bras (1992). 2015 Jan-Feb;61(1):19-20. doi: 10.1590/1806-9282.61.01.019. Epub 2015 Jan 1. Erratum in: Rev Assoc Med Bras (1992). 2015 May-Jun;61(3):290. Torres, Yaniel Castro [corrected to Castro-Torres, Yaniel].


Renal denervation with vincristine for the treatment of resistant hypertension: further investigations are needed to implement it globally.

Castro Torres Y, Katholi RE.

Hellenic J Cardiol. 2014 Nov-Dec;55(6):514-5. No abstract available.


Novel treatment approaches in hypertensive type 2 diabetic patients.

Castro Torres Y, Katholi RE.

World J Diabetes. 2014 Aug 15;5(4):536-45. doi: 10.4239/wjd.v5.i4.536. Review.


A controlled trial of renal denervation for resistant hypertension.

Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators..

N Engl J Med. 2014 Apr 10;370(15):1393-401. doi: 10.1056/NEJMoa1402670. Epub 2014 Mar 29.


Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel on Renal Sympathetic Denervation.

Angle JF, Prince EA, Matsumoto AH, Lohmeier TE, Roberts AM, Misra S, Razavi MK, Katholi RE, Sarin SN, Sica DA, Shivkumar K, Ahrar K.

J Vasc Interv Radiol. 2014 Apr;25(4):497-509. doi: 10.1016/j.jvir.2013.12.572. Review. No abstract available.


Renal denervation for treating resistant hypertension: current evidence and future insights from a global perspective.

Castro Torres Y, Katholi RE.

Int J Hypertens. 2013;2013:513214. doi: 10.1155/2013/513214. Epub 2013 Nov 27. Review.


Stenting and medical therapy for atherosclerotic renal-artery stenosis.

Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, Cohen DJ, Matsumoto AH, Steffes M, Jaff MR, Prince MR, Lewis EF, Tuttle KR, Shapiro JI, Rundback JH, Massaro JM, D'Agostino RB Sr, Dworkin LD; CORAL Investigators..

N Engl J Med. 2014 Jan 2;370(1):13-22. doi: 10.1056/NEJMoa1310753. Epub 2013 Nov 18.


Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study.

Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD.

Lancet. 2014 Feb 15;383(9917):622-9. doi: 10.1016/S0140-6736(13)62192-3. Epub 2013 Nov 7. Erratum in: Lancet. 2014 Feb 15;383(9917):602. Sobotka, Paul A [added].


International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension.

Schlaich MP, Schmieder RE, Bakris G, Blankestijn PJ, Böhm M, Campese VM, Francis DP, Grassi G, Hering D, Katholi R, Kjeldsen S, Krum H, Mahfoud F, Mancia G, Messerli FH, Narkiewicz K, Parati G, Rocha-Singh KJ, Ruilope LM, Rump LC, Sica DA, Sobotka PA, Tsioufis C, Vonend O, Weber MA, Williams B, Zeller T, Esler MD.

J Am Coll Cardiol. 2013 Dec 3;62(22):2031-45. doi: 10.1016/j.jacc.2013.08.1616. Epub 2013 Sep 18.


Renal sympathetic denervation for treatment-resistant hypertension…in moderation.

Rocha-Singh KJ, Katholi RE.

J Am Coll Cardiol. 2013 Nov 12;62(20):1887-9. doi: 10.1016/j.jacc.2013.06.020. Epub 2013 Jul 10. No abstract available.


Treatment of anemia with darbepoetin alfa in systolic heart failure.

Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ; RED-HF Committees.; RED-HF Investigators..

N Engl J Med. 2013 Mar 28;368(13):1210-9. doi: 10.1056/NEJMoa1214865. Epub 2013 Mar 10.


Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF).

McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Solomon SD, Tendera M, van Veldhuisen DJ, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB; RED-HF Committees Investigators..

Eur J Heart Fail. 2013 Mar;15(3):334-41. doi: 10.1093/eurjhf/hfs204. Epub 2013 Jan 17.


Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications.

Katholi RE, Couri DM.

Int J Hypertens. 2011;2011:495349. doi: 10.4061/2011/495349. Epub 2011 Jun 30.


Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months.

Symplicity HTN-1 Investigators..

Hypertension. 2011 May;57(5):911-7. doi: 10.1161/HYPERTENSIONAHA.110.163014. Epub 2011 Mar 14.


Catheter-based renal sympathetic denervation reduces systolic blood pressure by 32 mm Hg in people with treatment-resistant hypertension.

Katholi RE, Rocha-Singh KJ.

Evid Based Med. 2011 Aug;16(4):109-10. doi: 10.1136/ebm1194. Epub 2011 Mar 3. No abstract available.


Renal nerves in the maintenance of hypertension: a potential therapeutic target.

Katholi RE, Rocha-Singh KJ, Goswami NJ, Sobotka PA.

Curr Hypertens Rep. 2010 Jun;12(3):196-204. doi: 10.1007/s11906-010-0108-4. Review.


The role of renal sympathetic nerves in hypertension: has percutaneous renal denervation refocused attention on their clinical significance?

Katholi RE, Rocha-Singh KJ.

Prog Cardiovasc Dis. 2009 Nov-Dec;52(3):243-8. doi: 10.1016/j.pcad.2009.09.003. Review.


Contrast-induced nephropathy-choice of contrast agents to reduce renal risk.

Katholi RE.

Am Heart Hosp J. 2009 Summer;7(1):45-9. Review.


Supplemental Content

Loading ...
Support Center